EVERGLADES BIOPHARMA LLC — Department of Health and Human Services STTR Phase I: W

Description

Project Summary Diabetic retinopathy DR is a leading cause of vision loss affecting about million people worldwide A major breakthrough in DR therapy is the recent approval of vascular endothelial growth factor VEGF inhibitors However anti VEGF therapy has limited efficacy with a number of side effects The critical barrier is how to identify other angiogenic targets for alternative or combination therapy of anti VEGF resistant DR We have discovered a novel DR associated angiogenic factor that selectively binds to and stimulates angiogenesis of diseased but not normal vessels In contrast VEGF binds to and induces the angiogenesis of both diseased and normal vasculature This new ligand has a different receptor pathway than VEGF and therefore their inhibitors will have different spectra of anti angiogenic activity for alternative or combination therapy of DR We developed a monoclonal antibody against this new target and demonstrated its capacity to alleviate DR in mice with high efficacy Based on the normal phenotype of the knockout mice we predicted and confirmed that the therapeutic antibody at an excessively high dose has minimal side effects Therefore anti angiogenic therapy against this new ligand has the advantages of high efficacy minimal side effects and a different mechanism of action than anti VEGF Antibody humanization is an essential step for the translation of this novel therapy This project will humanize the monoclonal antibody Aim Humanized antibodies will be selected based on their ligand binding affinity neutralizing activity therapeutic efficacy and side effects Aim Humanized antibody with optimal therapeutic activity and minimal side effects will be used for clinical trials in the next phase Therefore this project will lead to the development of a new drug for anti angiogenic therapy of DR with high efficacy and safety Project Narrative This project is to develop a humanized antibody against a novel angiogenic ligand for clinical therapy of diabetic retinopathy with high efficacy and minimal side effects The academic partner has discovered this novel angiogenic factor characterized its pathogenic role and developed a monoclonal antibody against this ligand with therapeutic activity In this project the small business partner will humanize the monoclonal antibody and the academic partners will evaluate humanized antibodies for their therapeutic efficacy and toxicity This project will convert a monoclonal antibody into a new drug for the therapy of diabetic retinopathy with high efficacy and safety